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bjectives This study sought to evaluate the safety and efﬁcacy of drug-eluting stents (DES) com-
ared with bare-metal stents (BMS) in patients with insulin- and noninsulin-treated diabetes.
ackground Diabetes is a powerful predictor of adverse events after percutaneous coronary inter-
entions (PCI), and insulin-treated diabetic patients have worse outcomes. The DES are efﬁcacious
mong patients with diabetes; however, their safety and efﬁcacy, compared with BMS, among insu-
in-treated versus noninsulin-treated diabetic patients is not well established.
ethods Using the National Heart, Lung, and Blood Institute Dynamic Registry, we evaluated 1-year
utcomes of insulin-treated (n  817) and noninsulin-treated (n  1,749) patients with diabetes
ho underwent PCI with DES versus BMS.
esults The use of DES, compared with BMS, was associated with a lower risk for repeat revascular-
zation for both noninsulin-treated patients (adjusted hazard ratio [HR]  0.59, 95% conﬁdence in-
erval [CI] 0.45 to 0.76) and insulin-treated subjects (adjusted HR  0.63, 95% CI 0.44 to 0.90). With
espect to safety in the overall diabetic population, DES use was associated with a reduction of
eath or myocardial infarction (adjusted HR  0.75, 95% CI 0.58 to 0.96). However, this beneﬁt was
onﬁned to the population of noninsulin-treated patients (adjusted HR  0.57, 95% CI 0.41 to 0.81).
mong insulin-treated patients, there was no difference in death or myocardial infarction risk be-
ween DES- and BMS-treated patients (adjusted HR  0.95, 95% CI 0.65 to 1.39).
onclusions Drug-eluting stents are associated with lower risk for repeat revascularization
ompared with BMS in treating coronary artery disease among patients with either insulin- or
oninsulin-treated diabetes. In addition, DES use is not associated with any signiﬁcant increased
afety risk compared with BMS. These ﬁndings suggest that DES should be the preferred strategy
or diabetic patients. (J Am Coll Cardiol Intv 2008;1:139–47) © 2008 by the American College of
ardiology Foundation
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140iabetes mellitus is a risk factor for cardiovascular disease
1). Although intracoronary stenting is routinely used to
reat coronary disease, clinical and angiographic outcomes
or diabetic patients compared with nondiabetic individuals
re worse. Diabetes remains a strong predictor of adverse
rognoses in patients undergoing percutaneous coronary
ntervention (PCI) (2,3). The clinical efficacy of drug-
luting stents (DES), by reducing the need for repeat
evascularization, has resulted in their widespread use (4,5).
See page 148
Within the diabetic population, the use of insulin therapy
s associated with a worse cardiovascular prognosis than
ound in those patients treated with oral hypoglycemic
rugs or diet (6–9). Restenosis rates and mortality after PCI
re higher among insulin-treated patients than among
oninsulin-treated diabetic patients (9,10). Although DES
re effective for the prevention of restenosis, their efficacy
mong insulin-treated patients has not been fully elucidated
(11,12). Moreover, despite their
short-term efficacy, several re-
cent reports suggest that DES
are associated with late stent
thrombosis, and diabetes melli-
tus is itself a risk factor for this
(13–15). However, the safety of
DES, in relation to bare-metal
stents (BMS), among insulin-
treated diabetic patients has not
been reported.
Therefore, we investigated the
safety and efficacy of DES com-
pared with BMS among diabet-
cs according to whether or not insulin treatment was part of
heir therapy. We used the National Heart, Lung, and
lood Institute (NHLBI) Dynamic Registry to evaluate
-year outcomes of insulin- and noninsulin-treated patients
ith diabetes who underwent percutaneous coronary inter-
ention with DES versus those who received BMS.
ethods
HLBI Registry design. The Registry, coordinated at the
niversity of Pittsburgh, includes 23 sites across North
merica that enrolled consecutive patients undergoing
CI at several periods of time or waves. Recruitment of
0,962 patients into the 5 waves occurred as follows:
ave 1 (July 1997 to February 1998, n  2,524), Wave
(February 1999 to June 1999, n  2,105), Wave 3
October 2001 to March 2002, n  2,047), Wave 4
February 2004 to May 2004, n  2,112), and Wave 5
February 2006 to August 2006, n  2,174). The
bbreviations
nd Acronyms
MS  bare metal stent(s)
ABG  coronary artery
ypass graft
I  confidence interval
ES  drug-eluting stent(s)
R  hazard ratio
I  myocardial infarction
CI  percutaneous
oronary interventionirolimus-eluting stent was approved by the U.S. Food Snd Drug Administration (FDA) in March 2003 and was
vailable at all Registry sites by the time Wave 4 began.
he paclitaxel-eluting stent was approved by the FDA in
pril 2004 and was available at all sites at that time.
Methods of data collection, quality assurance, and defi-
ition of terms have been previously described (16,17). Data
ollected included baseline demographic, clinical, angio-
raphic, and procedural characteristics, during the index
CI, as well as the incidence of death, myocardial infarction
MI), and the need for coronary artery bypass graft (CABG)
urgery during hospitalization. In-hospital and 12-month
ollow-up data were collected by research coordinators using
tandardized report forms, guided by a manual of opera-
ions. Medical records were reviewed for patients requiring
epeat hospitalization. Follow-up coronary angiography was
btained only if clinically indicated.
tudy population. The analyses evaluate the course of all
iabetics within Waves 1 to 5 who underwent PCI, catego-
ized by the type of stents received (BMS versus DES) and by
iabetes treatment (insulin- vs. noninsulin-treated). To mini-
ize selection bias, for those patients enrolled during Waves 4
nd 5 (i.e., when both DES and BMS were available), only
iabetic patients who received a DES were included in the
nalysis, whereas Wave 4 and 5 patients treated with BMS
ere excluded (n  297). Analyses of the Wave 4 and 5
atients who received a BMS suggest that these subjects were
f higher clinical risk than the BMS-treated patients from
arlier waves and were thus not included in these analyses. Use
f DES across U.S. sites was relatively uniform. The Dynamic
egistry identified study patients with diabetes according to
he use of oral hypoglycemic agents, diet, or treatment with
nsulin. Patients on both insulin and oral therapy were catego-
ized into the insulin-treated group. Seventy-two patients who
eceived a combination of DES and BMS were included in the
ES group. Analyses were performed both by including and
xcluding such patients. Angiograms were analyzed by visual
stimates of lesion stenosis, lesion length, and diameter
tenosis.
linical outcomes. Patients were followed up prospectively
or 12 months to ascertain death, MI, CABG surgery,
epeat PCI, and repeat revascularization (PCI/CABG). The
rimary outcomes were analyzed as time to event, with the
ollow-up time measured in days from study entry (index
CI) to the date of the first event among death, MI,
ABG, or repeat PCI. Those who were event-free were
ensored 12 months after study entry. Stent thrombosis was
ot tracked during Waves 1 to 3 and thus was not
pecifically included in this analysis.
tatistical analysis. Patient characteristics pertaining to
he index PCI, including demographics, medical history,
ardiac presentation, periprocedural medications, proce-
ural characteristics, and outcomes, were compared by
tudent t tests and chi-square tests (asymptotic or Fisher
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141xact test) for categorical variables for comparisons by
iabetes treatment and by stent received. One-year cu-
ulative incidence rates of clinical outcomes (e.g., death,
I, repeat PCI, and CABG) and composite outcomes
e.g., repeat PCI/CABG, death/MI) were estimated by
he Kaplan-Meier method and tested by the log-rank
tatistic. Multivariable Cox proportional hazards regres-
ion was used with cardiac events as the outcome with
MS as the referent category. Fully adjusted 1-year
utcome models were fit that included demographic
haracteristics, clinical variables, and procedural and
esion characteristics as explanatory variables for adjust-
ent. Covariates were selected by forward stepwise
ethods and those considered to be biologically relevant.
Table 1. Baseline Clinical Characteristics and Risk Factors by Diabetes Tr
Insulin-Treated
BMS
(n  444)
DES
(n  373)
p Value
BMS Versus D
Mean age, yrs 63.9 63.0 0.39
Female, % 53.4 45.3 0.02
Race, % 0.03
White 71.3 62.5
Black 17.6 26.1
Hispanic 7.9 6.7
Asian 2.9 4.0
Other 0.2 0.5
Mean body mass index (kg/m2) 31.0 32.2 0.01
Prior PCI, % 0.008
None 65.5 58.4
1 21.2 20.1
1 13.3 21.4
Prior CABG 0.59
None 72.3 69.2
1 25.0 28.2
1 2.7 2.7
Prior myocardial infarction 38.9 31.2 0.02
Concomitant diseases, %
Severe noncardiac comorbidity 52.6 59.1 0.06
Cerebrovascular 10.4 11.7 0.56
Renal 16.3 29.0 0.001
Peripheral vascular disease 18.5 13.6 0.06
Pulmonary 13.3 10.0 0.15
Cancer 7.2 9.2 0.30
Other 17.2 21.1 0.15
Congestive heart failure, % 23.9 20.9 0.32
Hypertension, % 80.8 88.8 0.002
Hypercholesterolemia, % 73.8 85.1 0.001
Smoking, % 0.76
Never 39.7 42.2
Current 17.0 16.8
Former 43.4 41.0BMS bare-metal stent; CABG coronary artery bypass graft; PCI percutaneous coronary intervention;esults
aseline patient characteristics. A total of 9,170 (84%)
atients received stents, and the 1-year rate of follow-up was
6%. Among those receiving stents, 817 (8.9%) were
nsulin-treated diabetic patients, and 1,749 (19.1%) were
oninsulin-treated diabetic patients. Within the insulin-
reated group, 373 (45.7%) were patients treated with DES
nd 444 (54.3%) were patients treated with BMS, whereas
he noninsulin-treated group consisted of 779 (44.5%)
atients treated with DES and 970 (55.5%) patients treated
ith BMS. Table 1 lists the baseline characteristics. There
as no significant difference in age, but the insulin-treated
atients were more likely to be female, to be nonwhite, and
nt
Noninsulin-Treated
BMS
(n  970)
DES
(n  779)
p Value
BMS Versus DES
p Value Insulin-Treated
Versus Noninsulin-Treated
64.4 64.0 0.39 0.15
41.6 35.4 0.008 0.001
0.002 0.001
71.5 69.4
12.5 16.7
8.8 10.2
6.6 3.6
0.6 0.1
30.3 31.4 0.001 0.06
0.001 0.006
70.1 60.1
20.1 24.5
9.8 15.5
0.56 0.001
82.4 81.6
15.1 16.5
2.5 1.9
33.4 27.3 0.006 0.02
39.6 40.1 0.83 0.001
8.8 7.8 0.43 0.03
6.8 11.0 0.002 0.001
8.8 9.8 0.46 0.001
9.0 8.5 0.73 0.02
6.8 7.6 0.52 0.40
12.6 13.2 0.73 0.001
16.1 12.0 0.02 0.001
77.4 88.7 0.001 0.21
68.4 86.2 0.001 0.16
0.66 0.09
37.3 35.2
18.8 19.9
43.9 44.9eatme
ESDES drug-eluting stent.
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142o present with more cardiovascular comorbidities, includ-
ng prior revascularization, cerebrovascular disease, renal
nsufficiency, peripheral vascular disease, and congestive
eart failure. Those receiving DES, compared with BMS,
ere more likely to have hypertension, hypercholesterol-
mia, and concomitant renal insufficiency, but were less
ikely to have a history of congestive heart failure. As shown
n Table 2, the insulin-treated patients had a greater extent
f atherosclerotic burden. In comparing DES versus BMS,
here were no important differences in angiographic char-
cteristics, except that the DES groups had longer lesion
engths.
rocedural and lesion characteristics. Table 3 illustrates the
rocedural and lesion characteristics. The lesions intervened on
n the insulin-treated patients were more likely to be complex
nd calcified. Among the entire cohort, patients receiving
MS were more likely to have unstable angina and angio-
raphic evidence of thrombus within treated lesions compared
ith those who received DES, who were more likely to be
resent with stable symptoms. However, there were no signif-
cant differences observed relating to setting of the procedure
i.e., elective, urgent, or emergent). There was greater use of
lycoprotein IIb/IIIa inhibitors in the noninsulin-treated
Table 2. Angiographic Characteristics by Diabetes Treatment
Insulin-Treated
BMS
(n  444)
DES
(n  373)
p Va
BMS Ver
Mean left ventricular function, % 48.7 50.0 0.1
Abnormal left ventricular function, % 41.1 36.7 0.2
Coronary artery lesion location, %
Left anterior descending only 15.4 14.5 0.7
Left circumﬂex only 5.6 7.5 0.2
Right coronary only 10.7 6.7 0.0
Left anterior descending, left circumﬂex,
and right coronary
36.9 40.5 0.3
Number of vessels diseased, % 0.7
Single-vessel 29.3 26.5
Double-vessel 32.1 31.4
Three-vessel 38.1 41.6
Percent with stenoses 50% in diameter
Left main coronary artery 7.7 7.5 0.9
Left anterior descending artery 74.8 77.7 0.3
Left circumﬂex artery 60.6 65.1 0.1
Right coronary artery 70.7 69.4 0.6
Bypass graft 19.8 22.0 0.4
Any total occlusions 46.2 45.6 0.8
Mean number of signiﬁcant lesions 3.5 3.8 0.1
Amenable to complete revascularization
by PCI, %
71.6 83.3 0.0
Amenable to complete revascularization
by CABG, %
75.9 72.6 0.2Abbreviations as in Table 1.roup treated with BMS. Mean stented length was longer
mong the DES-treated patients by 3.5 mm.
linical outcomes. There were no significant differences in
0-day outcomes of death, MI, or repeat revascularization
y diabetes regimen or use of DES versus BMS (data not
hown). Table 4 shows the 1-year event rates in each of the
groups. The risk of repeat revascularization among the
ntire diabetic cohort was significantly lower with DES
ompared with BMS (13.7% vs. 21%, p  0.001). Among
ll DES-treated diabetic patients, there were no significant
ifferences (data not shown) in 1-year death, MI, or repeat
evascularization when comparing sirolimus-eluting stents
n 752) versus paclitaxel-eluting stents (n 364). As seen
n Table 4 and in Figure 1, there were significant differences
n revascularization outcomes between the insulin- and
oninsulin-treated diabetic patients. Compared with BMS,
he use of DES was associated with significantly lower rates
f 1-year need for repeat PCI among noninsulin-treated
atients (11.2% vs. 15.6%, p  0.008), but not among the
nsulin-treated diabetic patients (14.1% vs. 18.1%, p 
.17). The 1-year cumulative rate of repeat revascularization
as statistically significantly lower in the DES-treated
atients among the noninsulin-treated diabetic group
Noninsulin-Treated
S
BMS
(n  970)
DES
(n  779)
p Value
BMS Versus DES
p Value Insulin-Treated
Versus Noninsulin-Treated
51.7 52.0 0.62 0.01
34.3 30.3 0.12 0.005
18.9 15.1 0.04 0.17
6.9 7.9 0.40 0.45
11.6 8.2 0.02 0.34
29.7 35.4 0.01 0.002
0.03 0.03
35.5 29.3
32.5 33.2
31.8 37.0
5.3 6.3 0.36 0.07
73.9 76.1 0.29 0.50
54.9 62.4 0.002 0.03
64.4 66.0 0.50 0.01
13.2 11.6 0.30 0.001
37.9 37.4 0.80 0.001
3.2 3.3 0.04 0.001
78.8 89.6 0.001 0.001
81.8 77.3 0.02 0.003lue
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14313.1% vs. 20.4%, p  0.001) as well as the insulin-treated
roup (14.9% vs. 22.3%, p  0.02). There were no signif-
cant changes in these findings when the patients who
Table 3. Procedural and Lesion Characteristics by Diabetes Treatment and
Insulin-Treated
Procedural
BMS
(n  444)
DES
(n  373)
p Value
BMS Versus D
Reason for revascularization, %
Asymptomatic coronary artery
disease
6.1 12.9 0.001
Stable angina 20.0 17.4 0.34
Unstable angina 47.1 38.9 0.02
Acute myocardial infarction 23.0 22.8 0.95
Cardiogenic shock 2.9 0.5 0.01
Circumstances of procedure, % 0.84
Elective 60.8 59.8
Urgent 32.0 31.9
Emergent 7.2 8.3
Glycoprotein IIb/IIIa inhibitor use, % 35.6 34.3 0.70
Lesions
BMS
(n  656)
DES
(n  527)
p Value
BMS Versus D
ACC/AHA lesion classiﬁcation, % 0.17
A 13.1 11.5
B1 29.2 27.7
B2 34.2 31.5
C 23.5 29.2
Reference vessel size, mm 3.0 3.0 0.92
Mean lesion length, mm 12.9 17.5 0.001
Mean diameter stenosis, % 83.1 82.7 0.02
Evidence of thrombus, % 15.2 12.0 0.12
Ulcerated, % 13.0 12.8 0.91
Bifurcation, % 10.4 8.0 0.17
Calciﬁed, % 29.2 32.9 0.17
DES type
Sirolimus 62.0 N/A
Paclitaxel 31.3 N/A
ACC/AHA American College of Cardiology/American Heart Association; N/A not applicable; ot
Table 4. Cumulative Event Rates for 1-Year Follow-Up by Diabetes Treatme
All Diabetes Patients
BMS
(n  1,414)
DES
(n  1,152) p Value
Death 8.5 5.4 0.003
Myocardial infarction 6.6 5.9 0.52
Coronary artery bypass graft 6.5 2.1 0.001
Repeat PCI 16.4 12.1 0.003
Death/myocardial infarction 13.8 10.3 0.001
CABG/repeat PCI 21 13.7 0.001
Death/MI/repeat PCI/CABG 29.8 20.1 0.001Abbreviations as in Table 1.eceived a combination of both DES and BMS were
xcluded from the analysis. Furthermore, no differences
ere observed between paclitaxel-eluting stents and
of Stent Received
Noninsulin-Treated
BMS
(n  970)
DES
(n  779)
p Value
BMS Versus DES
p Value Insulin-Treated
Versus Noninsulin-Treated
5.9 14.1 0.001 0.76
19.8 22.1 0.24 0.25
45.8 35.7 0.001 0.33
23.5 23.4 0.96 0.75
2.6 0.4 0.0003 0.67
0.18 0.23
57.0 61.1
32.4 30.2
10.6 8.7
39.9 33.2 0.004 0.34
BMS
(n  1,458)
DES
(n  1,117)
p Value
BMS Versus DES
p Value Insulin-Treated
Versus Noninsulin-Treated
0.001 0.002
12.9 9.5
34.2 34.0
34.4 30.8
18.5 25.7
3.0 3.0 0.11 0.18
13.2 16.9 0.001 0.43
82.8 83.3 0.21 0.63
16.0 10.0 0.001 0.76
12.1 12.0 0.93 0.45
11.2 9.4 0.15 0.31
25.1 30.2 0.005 0.03
61.2 N/A 0.97
31.7 N/A 0.57
reviations as in Table 1.
d Type of Stent Received
Insulin-Treated Noninsulin-Treated
S
444)
DES
(n  373) p Value
BMS
(n  970)
DES
(n  779) p Value
.8 8.4 0.52 7.8 3.9 0.001
.8 10 0.29 6 4 0.07
.1 1.8 0.02 7.2 2.3 0.001
.1 14.1 0.17 15.6 11.2 0.008
15.8 0.99 12.7 7.6 0.001
.3 14.9 0.02 20.4 13.1 0.001
.3 24.5 0.03 28.6 18.5 0.001Type
ES
ESnt an
BM
(n 
9
7
5
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16
22
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144irolimus-eluting stents within either the insulin- or
oninsulin-treated populations.
Overall, as seen in Table 4, among the entire diabetic
opulation studied, the hazard ratio (HR) of death and MI
t 1 year was significantly lower among the DES-treated
atients compared with the BMS-treated patients (10.3%
s. 13.8%, p  0.001). However, as seen in Figure 2, this
enefit was only observed in the population of noninsulin-
reated patients (7.6% vs. 12.7%, p  0.001), whereas
mong insulin-treated patients, there was no difference in
eath or MI risk between DES- and BMS-treated patients
Figure 1. Repeat Revascularization Event Rates
Kaplan-Meier 1-year curves of the incidence of the composite endpoint of pos
bypass graft (CABG) by diabetes treatment regimen and use of drug-eluting st
Figure 2. Death or Myocardial Infarction Event Rates
Kaplan-Meier 1-year curves of the incidence of the composite end point of de
versus BMS. Abbreviations as in Figure 1.15.8% vs. 16%, p  0.99). In evaluating the entire diabetic
ohort, there was a reduction in the combined outcome of
eath, MI, and repeat revascularization with DES com-
ared with BMS (20.1% vs. 29.8%, p 0.001). This benefit
as appreciated in both the insulin- and noninsulin-treated
ubjects (Table 4).
Figure 3 shows adjusted relative risks for adverse
utcomes for the 4 groups, with variables adjusted for
etailed in the figure legend. Overall, the use of DES was
fficacious and safe in both the insulin- and noninsulin-
reated groups. In noninsulin-treated patients, the use of
arge repeat percutaneous coronary intervention (PCI) or coronary artery
ES) versus bare-metal stent (BMS).
myocardial infarction (MI) by diabetes treatment regimen and use of DESt-dischath or
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145ES was associated with an estimated 35% lower risk of
epeat PCI (adjusted HR  0.65, 95% confidence inter-
al [CI] 0.49 to 0.87, p  0.003), 41% lower risk of
epeat revascularization (adjusted HR  0.59, 95% CI
.45 to 0.76, p  0.0001), and 43% lower risk of death or
I (adjusted HR  0.57, 95% CI 0.41 to 0.81, p 
.001). Among insulin-treated patients, the adjusted
elative risk estimates related to use of DES for repeat
CI among the insulin-treated group showed a trend
oward significance with a 24% lower risk for repeat PCI
adjusted HR  0.76, 95% CI 0.52 to 1.11, p  0.15)
nd a 37% lower risk for repeat revascularization (ad-
usted HR  0.63, 95% CI 0.44 to 0.90, p  0.01). There
as virtually no difference in the adjusted risk of death or
I with DES use (adjusted HR  0.95, 95% CI 0.65 to
.39, p  0.79). With respect to the combined outcome
f death, MI, and repeat revascularization, after adjust-
ent, DES use was associated with a significant decrease
n event rates in the noninsulin-treated group (adjusted
R 0.65, 95% CI 0.52 to 0.82, p  0.001) but not in the
nsulin-treated group (adjusted HR 0.79, 95% CI 0.60 to
.04, p  0.1). Tests for interactions between stent type
nd treatment (insulin- vs. noninsulin-treated) showed
o significant effect.
iscussion
his study is among the first to focus exclusively on the
Figure 3. Relative Benefit of DES Over BMS for Safety and Efficacy
Adjusted hazard ratios (solid squares) and 95% conﬁdence intervals (horizontal
treated (referent category) patients, stratiﬁed by diabetes treatment regimen. Varia
hypertension, prior coronary intervention, peripheral vascular disease, history of hy
occlusion, tortuous lesion, unstable angina, acute myocardial infarction, cardiogen
attempted a class C lesion, attempted lesion receiving collaterals, attempted throm
blockers, calcium blocker, long-acting nitrates, angiotensin-converting enzyme inhafety and efficacy of DES among patients with diabetes tellitus stratified by insulin therapy. The primary finding is
he beneficial effect of DES in reducing the need for repeat
evascularization in both insulin- and noninsulin-treated
iabetic patients as compared with BMS. Several studies
ave documented the benefit of DES over BMS among
oninsulin-treated diabetic patients (5). Our results confirm
hese observations and extend this benefit to insulin-treated
atients as well, without evidence of increased hazard. This
enefit in the insulin-treated population is particularly
oteworthy given the baseline differences between the
roups. Compared with the BMS-treated patients, those
ho received DES had higher rates of hypertension, hyper-
holesterolemia, and renal insufficiency, and had longer
esion lengths. Despite the fact that these characteristics
ortend worse outcomes, DES was still found to be bene-
cial over BMS.
The rates of repeat revascularization observed in our
tudy are consistent with findings from prior studies. In the
rst ARTS I (Arterial Revascularization Therapy Study),
he 1-year rate of repeat revascularization for BMS in the
iabetic patient subgroup was 22.3%, which is similar to our
ndings with rates of 20.4% and 22.3% among noninsulin-
nd insulin-treated patients, respectively (18). Similarly, in
he ARTS II trial, 12.6% of DES-treated diabetic patients
equired repeat revascularization by 1 year (18). In our
tudy, the DES-treated groups had repeat revascularization
ates of 13.1% and 14.9% among noninsulin- and insulin-
for safety and efﬁcacy outcomes at 1-year comparing DES-treated versus BMS-
djusted for included age, vessel disease, history of congestive heart failure,
olesterolemia, number of signiﬁcant lesions, renal disease, presence of total
k, emergency procedure, urgent procedure, attempted an ostial lesion,
nd discharge medication (i.e., presence of at least 2 of the following: beta-
, statins, clopidogrel/ticlopidine). Abbreviations as in Figure 1.lines)
bles a
perch
ic shoc
bus, areated patients, respectively.
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146Our results support those from the DIABETES (Diabe-
es and Sirolimus-Eluting Stent) study, in which the ben-
ficial impact of DES over BMS in reducing repeat PCI was
ompatible in both insulin- and noninsulin-treated diabetic
atients (5). However, in the SIRIUS (Sirolimus-Eluting
tent in De Novo Coronary Lesions) study, those who were
n insulin therapy did not have a significant benefit of DES
gainst target lesion revascularization (19), but our study
ad greater numbers of patients. In a trial comparing
irolimus-eluting versus paclitaxel-eluting stents, the 2
tents had similar outcomes in all diabetic patients; however,
mong insulin-treated patients, paclitaxel-eluting stents
ere associated with lower adverse event rates (20,21). We
ound no differences between the 2 DES stents currently
pproved by the FDA.
Recently, there has been a focus on the safety of DES for
ff-label indications. The FDA has noted that at least 60%
f DES use is off-label for indications including in-stent
estenosis, long lesions, CABG, and the use of overlapping
nd multiple stents in a single vessel (22). Our group has
lso confirmed the widespread use of DES for off-label
ndications (23). These characteristics are frequently seen
mong diabetes patients; therefore, there is interest in the
afety profile of DES in this group. Moreover, the safety of
ES has recently come into question with studies suggest-
ng that sirolimus-eluting stents are associated with in-
reased mortality in the diabetic population (24).
We showed no short-term (1-year) adverse safety issue as
t pertains to the outcome of death or MI among insulin-
reated diabetic patients treated with DES compared with
MS. After statistical adjustment, there was no difference in
ortality among insulin-treated patients regardless of the
tent used. However, it is notable that although an overall
eduction in death or MI was seen in the DES-treated
iabetic patients (compared with the BMS-treated diabetic
ubjects), this was limited only to the noninsulin-treated
ubjects. This finding may represent a real phenomenon in
hat there are several reports of restenosis resulting in
ncreased mortality, especially among diabetic patients (25).
herefore, it is plausible that DES, by prevention of
estenosis, may be associated with lower rates of death or
I. Still, our results should be cautiously interpreted
ecause it seems unlikely that there is an interaction
etween DES, noninsulin treatment, and mortality. There
ere important baseline differences between the BMS- and
ES-treated groups within this population. The BMS-
reated patients were more likely to present with unstable
ngina and with angiographic evidence for thrombus, both
haracteristics that may predispose them to worse clinical
utcomes, especially in the presence of diabetes mellitus
26). Furthermore, despite our efforts to statistically adjust
or several different variables, it is still possible that there are
onfounding variables that are unaccounted for and that can
artially explain some of these findings.The higher rate of mortality among the insulin-treated
atients is consistent with other studies showing a higher
ortality risk among insulin-requiring patients (27,28).
verall, however, the safety of DES versus BMS in the
igh-risk diabetic population is consistent with a recent
eta-analysis that showed a similar safety profile of DES in
hese patients (29). The safety of DES in insulin-treated
atients is an important finding given several recent reports
rom other registries suggesting that diabetes, particularly
nsulin-treated diabetes, is an independent predictor of stent
hrombosis (30,31). Although we did not specifically track
tent thrombosis in our study, the lack of significant
ifferences in mortality and MI between the DES-treated
nd BMS-treated patients suggests that the 1-year safety
rofile is favorable.
tudy limitations. The Dynamic Registry is not a random-
zed trial. The number of insulin-treated patients treated
ith DES was relatively modest; nonetheless, we were able
o identify significant differences. There may be residual
onfounding not fully accounted for in the multivariable
nalyses; however, the large cohort of patients and the
elative similarity in baseline variables between the DES and
he BMS groups argue in favor of the validity of the results.
nother limitation is that we may not be able to account for
he precise effect of changing patterns in pharmacologic
herapy of atherosclerosis and diabetes. We could not
ccount for the duration or degree of control of diabetes.
espite this, our results regarding rates of repeat revascu-
arization among insulin-treated and noninsulin-treated pa-
ients mimic those from other studies.
onclusions
ur results show the efficacy of DES over BMS in reducing
he need for repeat revascularization in insulin-treated as
ell as noninsulin-treated diabetic patients. In addition,
ES use is not associated with any significant increased
afety risk compared with BMS. These findings suggest that
ES should be the preferred strategy for patients with
iabetes.
eprint requests and correspondence: Dr. Suresh R. Mulukutla,
ardiovascular Institute, University of Pittsburgh, 200 Lothrop
treet, Pittsburgh, Pennsylvania 15213. E-mail: mulukutlasr@
pmc.edu.
EFERENCES
1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002;287:
2570–81.
2. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes
mellitus on early and late outcome after percutaneous transluminal
coronary angioplasty. Circulation 1995;91:979–89.3. Gurm HS, Sarembock IJ, Kereiakes DJ, et al. Use of bivalirudin during
percutaneous coronary intervention in patients with diabetes mellitus: an
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 2 , 2 0 0 8
A P R I L 2 0 0 8 : 1 3 9 – 4 7
Mulukutla et al.
Impact of DES in Insulin-Treated Diabetic Patients
147analysis from the randomized evaluation in percutaneous coronary
intervention linking Angiomax to reduced clinical events (REPLACE)-2
Trial. J Am Coll Cardiol 2005;45:1932–8.
4. Urban P, Gershlick A, Guagliumi G, et al. Safety of coronary
sirolimus-eluting stents in daily clinical practice: one-year follow-up of
the e-Cypher registry. Circulation 2006;113:1434–41.
5. Sabate M, Jimenez-Quevedo P, Angiolillo D, et al. Randomized
comparison of sirolimus-eluting stent versus standard stent for percu-
taneous coronary revascularization in diabetic patients: the diabetes and
sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:
2175–83.
6. BARI Investigators. Influence of diabetes on 5-year mortality and
morbidity in a randomized trial comparing CABG and PTCA in
patients with multivessel disease. Circulation 1997;96:1761–9.
7. Rozenman Y, Sapoznikov D, Gotsman M. Restenosis and progression
of coronary disease after balloon angioplasty in patients with diabetes
mellitus. Clin Cardiol 2000;23:890–4.
8. Carson JL, Scholz PM, Chen AY, et al. Diabetes mellitus increases
short-term mortality and morbidity in patients undergoing coronary
artery bypass graft surgery. J Am Coll Cardiol 2002;40:418–23.
9. Verghese M, Frye RL, Lennon R, Barsness GW, Holmes DR Jr.
Comparison of survival after successful percutaneous coronary inter-
vention of patients with diabetes mellitus receiving insulin versus those
receiving only diet and/or oral hypoglycemic agents. Am J Cardiol
2004;93:399–403.
0. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes
mellitus on acute and late clinical outcomes following coronary stent
implantation. J Am Coll Cardiol 1998;32:584–9.
1. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the
polymer-based paclitaxel-eluting TAXUS stent in patients with diabe-
tes mellitus: the TAXUS IV trial. J Am Coll Cardiol 2005;45:117–9.
2. Moussa I, Leon MB, Baim D, et al. Impact of sirolimus-eluting stents
on outcome in diabetic patients: a SIRIUS substudy. Circulation
2004;109:2273–8.
3. Pfisterer M, Brunner-La Rocca HB, Buser PT, et al. Late clinical
events after clopidogrel discontinuation may limit the benefit of
drug-eluting stents: an observational study of drug-eluting versus bare
metal stents. J Am Coll Cardiol 2006;48:2584–91.
4. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized con-
trolled trials comparing drug-eluting vs. bare metal stents in coronary
artery disease: a meta-analysis. Eur Heart J 2006;27:2784–814.
5. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent
thrombosis after implantation of sirolimus-eluting stents in diabetic
and nondiabetic patients: the EVASTENT matched-cohort registry.
J Am Coll Cardiol 2007;50:501–8.
6. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary
intervention in the current era compared with 1985-86; the National
Heart Lung and Blood Institute Registries. Circulation 2000;102:
2945–51.
7. Laskey WK, Williams DO, Vlachos HA, et al. Changes in the practice
of percutaneous coronary intervention: a comparison of enrollmentwaves in the National Heart Lung, and Blood Institute Dynamic
Registry. Am J Cardiol 2001;87:964–9.
8. Macaya C, Garcia-Garcia HM, Colombo A, et al. One-year results of
coronary revascularization in diabetic patients with multivessel coronary
artery disease. Sirolimus stent vs. coronary artery bypass surgery and
bare metal stent: insights from ARTS II and ARTS I. Euro Interv
2006;2:69–76.
9. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents
on outcome in diabetic patients. Circulation 2004;109:2273.
0. Simonton CA, Brodie B, Cheek C, et al. Comparative late clinical
outcomes of paclitaxel and sirolimus-eluting coronary stents in diabetic
patients from a large prospective multicenter registry: results from the
Strategic Transcatheter Evaluation of New Therapies (STENT)
Group. Presented at: Innovation in Intervention: i2 Summit 2006;
March 11–14, 2006: Atlanta, GA.
1. Patterson C, Mapera S, Li HH, et al. Comparative effects of paclitaxel
and rapamycin on smooth muscle migration and survival: role of
AKT-dependent signaling. Arterioscler Thromb Vasc Biol 2006;26:
1473–80.
2. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary
drug-eluting stents: report from the meeting of the Circulatory System
Medical Devices Advisory Panel of the Food and Drug Administration
Center for Devices and Radiologic Health, December 7–8, 2006.
Circulation 2007;115:2352–7
3. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare
metal and drug-eluting stents for off-label indications: findings from
the NHLBI Dynamic Registry. N Engl J Med 2008;358:342–52.
4. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A
pooled analysis of data comparing sirolimus-eluting stents with bare-
metal stents. N Engl J Med 2007;356:989–97.
5. Sobel BE. Acceleration of restenosis by diabetes: pathogenetic impli-
cations. Circulation 2001;103:1185–7.
6. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality
following acute coronary syndromes. JAMA 2007;298:765–75.
7. Antoniucci D, Valenti R, Migliorini A, et al. Impact of insulin-
requiring diabetes mellitus on effectiveness of reperfusion and outcome
of patients undergoing primary percutaneous coronary intervention for
acute myocardial infarction. Am J Cardiol 2004;93:1170–2.
8. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in
diabetic patients: a comparison of the randomized and observational
components of the Bypass Angioplasty Revascularization Investigation
(BARI). Circulation 1999;99:633–40.
9. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with
drug-eluting and bare-metal stents: a collaborative network meta-
analysis. Lancet 2007;370:937–48.
0. Iaokovu I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and
outcome of thrombosis after successful implantation of drug-eluting
stents. JAMA 2005;293:2126–30
1. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary
stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in
routine clinical practice: data from a large two-institutional cohort
study. Lancet 2007;369:667–78.
